Delphia Therapeutics raised $67M in a Series A financing led by GV, Nextech Invest, Polaris Innovation Fund, and Alexandria Venture Investments to pioneer activation lethality in cancer medicines.
Delphia Therapeutics raised $67M in a Series A financing led by GV, Nextech Invest, Polaris Innovation Fund, and Alexandria Venture Investments to pioneer activation lethality in cancer medicines.
05/02/24, 11:07 AM
Location
cambridgeMoney raised
$67 million
Industry
therapeutics
biotechnology
health care
Round Type
series a
Investors
Alexandria Venture Investments, Polaris Innovation Fund, Nextech Invest, Gv (Google Ventures)
Delphia Therapeutics launched to pioneer a new area of cancer biology called activation lethality, to develop first-in-class targeted cancer medicines with significant anti-tumor activity and more durable patient benefit.
Company Info
Location
cambridge, massachusetts, united states
Additional Info
Delphia Therapeutics is a biopharmaceutical company pioneering activation lethality, a new area of cancer therapeutics that target cancer's surprising vulnerability to oncogene overactivation. Delphia’s activation lethality platform offers the potential for first-in-class, targeted cancer medicines that are effective on their own while also combating the emergence of drug resistance to classic targeted therapies.